Literature DB >> 17332481

Heritability of lung disease severity in cystic fibrosis.

Lori L Vanscoy1, Scott M Blackman, Joseph M Collaco, Amanda Bowers, Teresa Lai, Kathleen Naughton, Marilyn Algire, Rita McWilliams, Suzanne Beck, Julie Hoover-Fong, Ada Hamosh, Dave Cutler, Garry R Cutting.   

Abstract

RATIONALE: Obstructive lung disease, the major cause of mortality in cystic fibrosis (CF), is poorly correlated with mutations in the disease-causing gene, indicating that other factors determine severity of lung disease.
OBJECTIVES: To quantify the contribution of modifier genes to variation in CF lung disease severity.
METHODS: Pulmonary function data from patients with CF living with their affected twin or sibling were converted into reference values based on both healthy and CF populations. The best measure of FEV(1) within the last year was used for cross-sectional analysis. FEV(1) measures collected over at least 4 years were used for longitudinal analysis. Genetic contribution to disease variation (i.e., heritability) was estimated in two ways: by comparing similarity of lung function in monozygous (MZ) twins (approximately 100% gene sharing) with that of dizygous (DZ) twins/siblings (approximately 50% gene sharing), and by comparing similarity of lung function measures for related siblings to similarity for all study subjects.
MEASUREMENTS AND MAIN RESULTS: Forty-seven MZ twin pairs, 10 DZ twin pairs, and 231 sibling pairs (of a total of 526 patients) with CF were studied. Correlations for all measures of lung function for MZ twins (0.82-0.91, p < 0.0001) were higher than for DZ twins and siblings (0.50-0.64, p < 0.001). Heritability estimates from both methods were consistent for each measure of lung function and ranged from 0.54 to 1.0. Heritability estimates generally increased after adjustment for differences in nutritional status (measured as body mass index z-score).
CONCLUSIONS: Our heritability estimates indicate substantial genetic control of variation in CF lung disease severity, independent of CFTR genotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332481      PMCID: PMC1899267          DOI: 10.1164/rccm.200608-1164OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  45 in total

1.  Evidence for major genes influencing pulmonary function in the NHLBI family heart study.

Authors:  J B Wilk; L Djousse; D K Arnett; S S Rich; M A Province; S C Hunt; R O Crapo; M Higgins; R H Myers
Journal:  Genet Epidemiol       Date:  2000-07       Impact factor: 2.135

2.  Heritability of longitudinal change in lung function. The Framingham study.

Authors:  D J Gottlieb; J B Wilk; M Harmon; J C Evans; O Joost; D Levy; G T O'Connor; R H Myers
Journal:  Am J Respir Crit Care Med       Date:  2001-11-01       Impact factor: 21.405

3.  Effect of choice of reference equation on analysis of pulmonary function in cystic fibrosis patients.

Authors:  M Rosenfeld; M S Pepe; G Longton; J Emerson; S FitzSimmons; W Morgan
Journal:  Pediatr Pulmonol       Date:  2001-03

4.  Human disease genes.

Authors:  G Jimenez-Sanchez; B Childs; D Valle
Journal:  Nature       Date:  2001-02-15       Impact factor: 49.962

5.  Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics.

Authors:  F Mekus; M Ballmann; I Bronsveld; J Bijman; H Veeze; B Tümmler
Journal:  Twin Res       Date:  2000-12

6.  The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States.

Authors:  M S Schechter; B J Shelton; P A Margolis; S C Fitzsimmons
Journal:  Am J Respir Crit Care Med       Date:  2001-05       Impact factor: 21.405

7.  Annual lung function changes in young patients with chronic lung disease.

Authors:  P J F M Merkus; H A W M Tiddens; J C de Jongste
Journal:  Eur Respir J       Date:  2002-05       Impact factor: 16.671

8.  European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations.

Authors:  C Koch; H Cuppens; M Rainisio; U Madessani; H Harms; M Hodson; G Mastella; J Navarro; B Strandvik; S McKenzie
Journal:  Pediatr Pulmonol       Date:  2001-01

9.  Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients.

Authors:  Mark D Schluchter; Michael W Konstan; Pamela B Davis
Journal:  Stat Med       Date:  2002-05-15       Impact factor: 2.373

10.  Development and evaluation of a PCR-based, line probe assay for the detection of 58 alleles in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Authors:  XinJing Wang; Angela Myers; Randall K Saiki; Garry R Cutting
Journal:  Clin Chem       Date:  2002-07       Impact factor: 8.327

View more
  87 in total

1.  Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function.

Authors:  J Michael Collaco; Scott M Blackman; John McGready; Kathleen M Naughton; Garry R Cutting
Journal:  J Pediatr       Date:  2010-06-30       Impact factor: 4.406

2.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

Review 3.  Genetic variation and clinical heterogeneity in cystic fibrosis.

Authors:  Mitchell L Drumm; Assem G Ziady; Pamela B Davis
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

Review 4.  Identifying modifier genes of monogenic disease: strategies and difficulties.

Authors:  Emmanuelle Génin; Josué Feingold; Françoise Clerget-Darpoux
Journal:  Hum Genet       Date:  2008-09-11       Impact factor: 4.132

Review 5.  Update in cystic fibrosis 2007.

Authors:  Frank J Accurso
Journal:  Am J Respir Crit Care Med       Date:  2008-05-15       Impact factor: 21.405

Review 6.  Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Jessica E Pittman; Garry Cutting; Stephanie D Davis; Thomas Ferkol; Richard Boucher
Journal:  Ann Am Thorac Soc       Date:  2014-04

Review 7.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

Review 8.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

9.  Modulation of cystic fibrosis lung disease by variants in interleukin-8.

Authors:  A D Hillian; D Londono; J M Dunn; K A B Goddard; R G Pace; M R Knowles; M L Drumm
Journal:  Genes Immun       Date:  2008-06-19       Impact factor: 2.676

10.  Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease.

Authors:  YuanYuan Gu; Isaac T W Harley; Lindsay B Henderson; Bruce J Aronow; Ilja Vietor; Lukas A Huber; John B Harley; Jeffrey R Kilpatrick; Carl D Langefeld; Adrienne H Williams; Anil G Jegga; Jing Chen; Marsha Wills-Karp; S Hasan Arshad; Susan L Ewart; Chloe L Thio; Leah M Flick; Marie-Dominique Filippi; H Leighton Grimes; Mitchell L Drumm; Garry R Cutting; Michael R Knowles; Christopher L Karp
Journal:  Nature       Date:  2009-02-25       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.